scholarly journals P-EUS01 Pancreatic metastases from Renal Cell Cancer; endosonographic features and outcomes of a rare clinical entity

2021 ◽  
Vol 108 (Supplement_9) ◽  
Author(s):  
Wafaa Ahmed ◽  
Muhammad Farman ◽  
Deepak Joshi ◽  
Phillip Harrison ◽  
John Devlin ◽  
...  

Abstract Background The pancreas is a rare site for metastatic deposits in the absence of disseminated metastatic disease. They can be difficult to differentiate from primary pancreatic malignancy based on the clinical history and radiological features alone. Renal cell cancer (RCC) is the most common source. We describe their endosonographic characteristics and clinical outcomes. Methods Patients undergoing EUS- FNB with a positive diagnosis of pancreatic metastatic disease from RCC from 2017 to 2019 were retrospectively identified. Recorded variables included patient demographics, endosonographic features and patient outcomes.  Results Five patients were identified. Mean age was 63 (range 53-72 years old). Mean time from diagnosis of the primary RCC to diagnosis of pancreatic metastasis was 12.75 years (range 6-18 years). All had resection of the primary lesion. Mean diameter on EUS was 37.80mm (range 15mm to 100mm).  The lesions were homogenous, well-circumscribed, hypoechoic and hypervascular. Tissue acquisition was performed using a 22G FNB needle. Two underwent surgical resection of the metastasis, one of which had recurrence at the surgical bed after 26 months.  One had disseminated malignancy at the time of diagnosis. One passed away prior to surgical resection.  Conclusions Pancreatic metastasis from renal cell cancer have characteristic endosonographic features and can present many years after initial diagnosis and resection.  EUS-FNB has a central role in confirming this diagnosis.

1997 ◽  
Vol 2 (1) ◽  
pp. 29-34
Author(s):  
Yoshihiko Tomita ◽  
Vladimir Bilim ◽  
Tomoyuki Imai ◽  
Masayuki Takeda ◽  
Kota Tahahashi ◽  
...  

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16106-e16106
Author(s):  
Alfred Chung ◽  
Shufeng Li ◽  
Sumit Shah ◽  
Alice C. Fan ◽  
Sandy Srinivas

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 516-516 ◽  
Author(s):  
Inga Peters ◽  
Christel Reese ◽  
Natalia Dubrowinskaja ◽  
Wiebke Inga Antonopoulos ◽  
Martin Krause ◽  
...  

516 Background: Transition from localized renal cell cancer (RCC) to metastatic disease is associated with an immense mortality. Beside clinicopathological risk estimation, a molecular prediction of metastatic risk from primary cancers with a sufficient diagnostic accuracy is not available. We biometrically identified a candidate metastasis associated methylation signature (MAMS) in a genome-wide in silico DNA methylation analysis of TCGA data and carried out a double evaluation study using tissues from localized RCC, primary metastatic RCC, and distant metastases. Methods: Candidate MAMS was identified by genome-wide random forest analyses of TCGA methylation level 3 data aiming for classification of 230 primary RCC without distant metastases and 52 metastasized tumors. Forty-nine pyrosequencing and/or quantitative methylation specific PCR analyses were established for a total of 20 candidate methylated loci. For evaluation of MAMS, DNA was isolated and bisulfite converted from the primary RCC tissue cohort (n=187) as well as 99 distant metastases. Localized RCCs consisted of 92 pT1a/b tumors (clear cell, 73; papillary, 16; chromophobe, 2; not classified, 1) without lymph node or distant metastases. RCC samples of primary metastatic disease were obtained from 31 patients. Results: Single candidate loci showed specific hypermethylation when metastatic tissues were compared to primary RCC samples. Random forest analysis showed that MAMS including nine methylation loci achieved a sensitivity of 93% and a specificity of 89% (AUC 0.95) for differentiation of localized RCC and metastases (chi square, p = 3.4*10-29). Positive, negative likelihood, and diagnostic odds ratios were 8.6, 0.08, and 108. Using this random forest model for prediction of primary RCCs associated with distant or lymph node metastases revealed a sensitivity of 58% and specificity of 94% (AUC 0.84, p = 1.0*10-9). Positive, negative likelihood, and diagnostic odds ratios were 9.2, 0.45, and 20.5. Conclusions: A negative MAMS test result retrospectively reduced the probability of metastasis 15-fold in the localized disease cohort, suggesting a prospective evaluation for a possible clinical translation of MAMS in handling RCC patients.


1996 ◽  
Vol 3 (5) ◽  
pp. 466-468 ◽  
Author(s):  
E.E. Piccinini ◽  
G. Ugolini ◽  
G. Rosati ◽  
N.C.M. Salfi ◽  
S. Marroccu ◽  
...  

Cureus ◽  
2014 ◽  
Author(s):  
Alexander Muacevic ◽  
Christoph Füerweger ◽  
Christoph Trumm ◽  
Philipp Nuhn ◽  
Michael Staehler

Sign in / Sign up

Export Citation Format

Share Document